Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biopharma News
Biosimilar Deals 2025
Biosimilar Deals 2026
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Diversity
Helen Macpherson
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Home / News / Pearce IP Blog

PEARCE IP BLOG

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

Generic Partners & Apotex Infringe valid Neurim Sleep Patent

Generic Partners & Apotex Infringe valid Neurim Sleep Patent

No Rest For Infringers of Valid Melatonin Patent in Australia

by , | Aug 30, 2024

CQMS has successfully opposed ESCO Group’s (ESCO) patent application AU 2018201726 (‘726) on the grounds of lack of support and sufficiency. We previously reported on an opposition between the same parties for a related patent family member AU 2018201710 (‘710). As with that case, the Delegate in the present opposition exercised his authority under section 60(3) of the Patents Act 1990 and raised the additional opposition ground of inutility, which was not asserted by CQMS.

read more
Pearce IP’s Founder & CEO is Australasian Lawyer’s 2024 Most Influential Lawyer (Changemaker)

Pearce IP’s Founder & CEO is Australasian Lawyer’s 2024 Most Influential Lawyer (Changemaker)

by | Aug 15, 2024

Pearce IP’s founder & CEO Naomi Pearce honoured by Australasian Lawyer’s The Most Influential Lawyers in Australia list for 2024.   Included in category of Changemaker for third consecutive year, 1 of 12 lawyers and 1 of 5 women across all disciplines awarded in this category. The only female founder and the only intellectual property specialist included on this list. 

read more
Fanatics about trade mark infringement, cancellation and honest concurrent use in Australia

Fanatics about trade mark infringement, cancellation and honest concurrent use in Australia

by | Aug 13, 2024

The IPKat has received and is pleased to host the following guest contribution by Kimberley Evans (Pearce IP) regarding a recent Australian decision concerning inter alia the honest concurrent use and own name defences under Australian trade mark law. Here’s what Kimberley writes:

Fanatics about trade mark infringement, cancellation and honest concurrent use in Australia

read more
Don’t Dig Your Own Hole Part 2

Don’t Dig Your Own Hole Part 2

by , | Jul 29, 2024

CQMS has successfully opposed ESCO Group’s (ESCO) patent application AU 2018201726 (‘726) on the grounds of lack of support and sufficiency. We previously reported on an opposition between the same parties for a related patent family member AU 2018201710 (‘710). As with that case, the Delegate in the present opposition exercised his authority under section 60(3) of the Patents Act 1990 and raised the additional opposition ground of inutility, which was not asserted by CQMS.

read more

Recent BioBlast® Updates

MSD’s Subcutaneous Keytruda® Approved in Korea; Q4/26 Launch Planned

May 20, 2026

On 20 May 2026, Korea Biomedical Review reported that Korea’s Ministry of Food and Drug Safety has approved MSD’s Keytruda SC™ (pembrolizumab and berahyaluronidase alfa) for 35 indications across 18 cancer types.  MSD plans to launch the product in Korea in Q4/2026.

Formycon/Klinge Launch Aflibercept Biosimilars in EU

May 19, 2026

On 19 May 2026, Formycon and Klinge Biopharma announced that the European launch of FYB203, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept, 2mg), commenced on 15 May 2026 in key European markets, including Germany, France and Italy.

New Indication Alert: Genentech’s Tecentriq® (Atezolizumab) FDA-Approved for Bladder Cancer

May 15, 2026

On 15 May 2026, Roche subsidiary Genentech announced that the FDA has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for adults with muscle-invasive bladder cancer (MIBC) who have circulating tumour DNA molecular residual disease (ctDNA MRD) after cystectomy, as identified by a specified MRD assay.

Alteogen’s Biosimilar Aflibercept Approved in Korea

May 15, 2026

On 15 May 2026, Alteogen announced that the Korean Ministry of Food and Drug Safety (MFDS) has granted marketing authorisation for Eyzanfy™/ALT-L9 (aflibercept, 2mg), biosimilar to Regeneron/Bayer’s Eylea®, for all approved reference indications.

BMS and Hengrui Pharma Enter US$15.2B Strategic Collaboration

May 12, 2026

On 12 May 2026, Bristol Myers Squibb (BMS) and Hengrui Pharma announced that they have entered into global strategic collaboration and licence agreements to advance 13 early stage innovative medicines across oncology, haematology and immunology.

Celltrion Acquires France-Based Gifrer, Expects KRW 250B Revenue Uplift

May 12, 2026

On 12 May 2026, Celltrion announced that it has acquired a 100% stake in France-based healthcare firm, Gifrer.  Gifrer operates more than 9,000 pharmacy sales channels and supply networks covering about 800 hospitals across France and will continue to operate independently post-acquisition. 

See Our BioBlast®

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Subscribe here